Navigation Links
Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
Date:12/8/2012

hase 2 and 3 program is under way.

Conference Call and Webcast Details
Pharmacyclics will be holding a conference call on Wednesday, December 12, 2012 at 8:30 AM ET. To participate in the conference call, please dial 1-877-407-0778 for domestic callers and 1-201-689-8565 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's website at www.pharmacyclics.com.

About the Pharmacyclics and Janssen Collaboration
Pharmacyclics and Janssen Biotech, Inc. entered into a worldwide collaboration on December 8, 2011, to develop and commercialize ibrutinib. Following regulatory approval, Pharmacyclics and Janssen will co-commercialize ibrutinib. Each company will lead development for specific indications as stipulated in a global development plan.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scient
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
2. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
3. Startling results in synthetic chemistry presented in Nature Chemistry
4. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
5. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
6. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
7. Promising Data Presented on GenVec Malaria Program
8. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
9. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Rainbow Scientific, Inc. (RSI), ... recently opened an online store to add customer ... lines developed and manufactured by Biological Industries, Inc. ... Biological Industries’ Nutristem® serum-free, xeno-free reagents for human ... cell (hESC) culture. , The online store ...
(Date:9/30/2014)... New Jersey (PRWEB) September 30, 2014 ... it has been chosen by the Parenteral Drug ... (November 18 and 19, 2014) on container closure integrity ... container closure integrity test methods and philosophies detailed in ... – Integrity Evaluation. The course will span ...
(Date:9/29/2014)... 2014 Each year in the ... medical attention. In the military, burn injury is ... battlefield medical care. More than 800 service members ... wounds heal slowly, remain inflamed and often become ... debilitating and functionally damaging. While developments in supportive ...
(Date:9/29/2014)... BEACH, Va. , Sept. 29, 2014 /PRNewswire-USNewswire/ ... from the fields of cartilage repair, regeneration, allograft ... attendees from around the world gathered to discuss ... LifeNet Health Institute of Regenerative Medicine symposium, ... Direction . Topics included Orthopedic Biosurgery, Minced Juvenile ...
Breaking Biology Technology:Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Faster Healing with Fewer Scars 2World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... 19 Abbott (NYSE:,ABT) will announce its 2008 third-quarter ... opens., The announcement will be followed by a ... Central time (9 a.m. Eastern), and will be,accessible through ... archived edition of the call will be,available after 11 ...
... China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... that at its 2008 Annual General Meeting ... the Company,s nominees to the,Board of Directors., ...
... Quarter 2008 Earnings Conference Call Tuesday, October 28, 2008, 5:00 ... p.m. U.S. EDT, FRAZER, Pa., Sept. ... quarter 2008 results for 5:00 p.m. EDT on Tuesday,October 28, 2008., ... October 28, 2008 Schedule, 4:10 p.m. EDT Q3 2008 results ...
Cached Biology Technology:China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... is available in German . ... behavioural response to risky situations such as exposure to ... now found in a long-term study on different populations ... metabolic rate and ambient temperature. High metabolic rates and ... in these scenarios birds were more likely to approach ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... study, scientists sampled the presence of 20 species of ... in the Adirondack Park. Calculating their occurrence at increasing ... are 36 percent more likely to occur near the ... that "human-sensitive" species were 26 percent less likely. Beyond ...
... of Nottingham has been used in a breakthrough study ... fully functioning fetal heart. The abdominal fetal ECG ... of Electrical and Electronic Engineering and on commercial sale ... company Monica Healthcare Ltd, has been used to observe ...
... to replace artificial preservatives in bread, making it tastier., ... mould fermented in sourdough bread, Michael Ganzle, professor and ... of Agricultural, Food and Nutritional Science and fellow researchers ... keep bread fresh without changing its flavour. Preservatives ...
Cached Biology News:WCS Adirondack Park study shows exurban residences impact bird communities up to 200 meters away 2WCS Adirondack Park study shows exurban residences impact bird communities up to 200 meters away 3Nottingham technology in heart development breakthrough 2Nottingham technology in heart development breakthrough 3Nottingham technology in heart development breakthrough 4
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: